ArticleTechnology in cancer research & treatment
Preoperative Ternary Classification of Pulmonary Ground-Glass Nodules (AIS/MIA/IAC): ResNet-10 Outperforms Radiomics and Clinicoradiographic Models in Multicenter Study.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pulmonary nodules: classification, biomarkers, signaling pathways, diseases, early diagnosis and management.Signal transduction and targeted therapy · 2026Review
- Ensemble machine learning classifiers based on computed tomography radiomics for predicting spread through air spaces in lung adenocarcinoma: a multicenter retrospective cohort study with transcriptomic interpretation.Quantitative imaging in medicine and surgery · 2026Article
- A novel multimodal model integrating CT-based deep learning and clinical information for predicting 1-year OS of first-line immunotherapy in ES-SCLC patients.Frontiers in oncology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionPreoperative differentiation among adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and invasive adenocarcinoma (IAC) is crucial for guiding ground-glass nodule (GGN) management. This multicenter study evaluated the comparative utility of deep learning (DL), radiomics, and conventional machine learning (cML)-based clinicoradiographic models for this ternary classification.MethodsWe developed four DL models (DenseNet-121, ResNet-10, ResNet-18, and VGG-13) for the ternary classification of AIS, MIA, and IAC using multicenter CT datasets. For comparative analysis, we constructed two additional classification models: (1) a radiomics model employing feature engineering through analysis of variance, recursive feature elimination with cross-validation, and least absolute shrinkage and selection operator, and (2) the cML-based clinicoradiographic model utilizing 12 different classifiers. The performance of all models was evaluated using the macro area under the curve (Macro-AUC) metric.Results847 GGNs postoperatively confirmed as lung adenocarcinoma were included in this multicenter study, which were randomly split into a training set (70%, n=592) and a validation set (30%, n=255). The DL model ResNet-10 demonstrated superior performance, achieving a Macro-AUC of 0.8055 (95% CI: 0.7723-0.8387), an accuracy of 0.6300 (95% CI: 0.5541-0.6764), and an F1-score of 0.4206 (95% CI: 0.3821-0.4598). This performance surpassed that of the radiomics model, which had a Macro-AUC of 0.7801 (95% CI: 0.7432-0.8170), an accuracy of 0.6100 (95% CI: 0.5276-0.6204), and an F1-score of 0.5505 (95% CI: 0.4983-0.6017), and the cML-based clinicoradiographic model, which achieved a Macro-AUC of 0.7770 (95% CI: 0.708-0.846), an accuracy of 0.6000 (95% CI: 0.5376-0.6604), and an F1-score of 0.4438 (95% CI: 0.3925-0.4961).ConclusionThe ResNet-10 network established a novel ternary classification model for predicting the invasiveness of GGNs. This approach provides clinically actionable insights that support surgical planning and facilitate risk-adapted management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.